ANG II-AT1 receptor pathway is involved in the anti-fibrotic effect of β-elemene

  • Rui Zhu (朱锐)
  • Ling Yang (杨玲)
  • Lin Shen (沈霖)
  • Jin Ye (叶进)
  • Jianguo Liu (刘建国)
  • Shenjun Hu (胡胜军)
Article

Abstract

To investigate the effects of β-elemene on the ANG II-AT1 receptor pathway in rats with liver fibrosis, a model of hepatic fibrosis was induced by hypodermical injection of carbon tetrachloride (CCl4) into Wistar male rats. β-elemene was intraperitonealy administered into the rats for 8 weeks (0.1 mL/100 g body weight per day). Masson staining was used to observe the liver fibrosis of rats and liver functions were measured by enzymatic kinetic analysis. The content of hydroxyproline in liver tissues was detected by specimen alkaline hydrolysis. The level of plasma ANG in blood II plasma was detected by radioimmunoassay. The expression of AT1R in rat liver were measured using reverse transcriptional-polymerase chain reaction and immunohistochemistry respectively. The results showed that β-elemene could reduce the collagen disposition in liver and inhibit the progression of liver fibrosis. In addition, the levels of plasma ANG II and the expression of hepatic AT1R in rats with liver fibrosis were also suppressed by β-elemene. It is concluded that the ANG II-AT1 receptor pathway plays an important role in the development of hepatic fibrosis and β-elemene could down-regulate the levels of plasma ANG II and the expression of hepatic AT1R in rats with liver fibrosis.

Key words

liver fibrosis β-elemene angiotensin II AT1 receptors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Albanis E, Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis, 2001,5(2): 315–334PubMedCrossRefGoogle Scholar
  2. 2.
    Matsusaka T, Ichikawa I. Biological functions of angiotensin and its receptors. Annu Rev Physiol, 1997,59: 395–412PubMedCrossRefGoogle Scholar
  3. 3.
    Bataller R, Ginès P, Nicolás JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000,118(6):1149–1156PubMedCrossRefGoogle Scholar
  4. 4.
    Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, 2001,34(4): 745–750PubMedGoogle Scholar
  5. 5.
    Paizis G, Cooper ME, Schembri JM, et al. Up-regulation of components of the renin-angiotensin system in the bile duct ligated rat liver. Gastroenterology, 2002,123(5): 1667–1676PubMedCrossRefGoogle Scholar
  6. 6.
    Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology, 2000,31(4): 828–833PubMedCrossRefGoogle Scholar
  7. 7.
    Ramalho LN, Ramalho FS, Zucoloto S, et al. Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology, 2002,49(48):1499–1502PubMedGoogle Scholar
  8. 8.
    Paizis G, Gilbert RE, Cooper ME, et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol, 2001,35(3):376–385PubMedCrossRefGoogle Scholar
  9. 9.
    Yoshiji H, Yoshii J, Ikenaka Y, et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol, 2002,37(1):22–30PubMedCrossRefGoogle Scholar
  10. 10.
    Wei HS, Lu HM, Li DG, et al. The regulatory role of AT1 receptor on activated HSCs in hepatic fibrogenesis: effects of RAS inhibitors on hepatic fibrosis induced by CCl4. World J Gastroenterol, 2000,6(6):824–828PubMedGoogle Scholar
  11. 11.
    Croquet V, Moal F, Veal N, et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol, 2002,37(6):773–780PubMedCrossRefGoogle Scholar
  12. 12.
    Liu C, Guo G, Hu ZY. Effect of zedoary rhizome on the renal interstitial fibrosis in rats induced unilateral ureteral obstruction. Shanghai J Tradit Chin Med, 2006,40(12): 71–73Google Scholar
  13. 13.
    Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem (Chinese), 1981,112(1): 70–75CrossRefGoogle Scholar
  14. 14.
    Oparil S, Haber E. The renin-angiotensin system. N Engl J Med, 1974,291(9):446–457PubMedCrossRefGoogle Scholar
  15. 15.
    Bataller R, Gines P, Nicolas JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology, 2000,118(6):1149–1156PubMedCrossRefGoogle Scholar
  16. 16.
    Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev, 1993,45:205–251PubMedGoogle Scholar
  17. 17.
    Li X, Meng Y, Wu P, et al. Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. Regul Pept, 2007,138(1):15–25PubMedCrossRefGoogle Scholar
  18. 18.
    Yoshiji H, Kuriyama S, Fukui H. Blockade of renin-angiotensin system in antifibrotic therapy. J Gastroenterol Hepatol, 2007,22(Suppl 1):S93–S95PubMedCrossRefGoogle Scholar
  19. 19.
    Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, 2001,34(4): 745–750PubMedGoogle Scholar
  20. 20.
    Yang L, Bataller R, Dulyx J, et al. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol, 2005,43(2):317–323.PubMedCrossRefGoogle Scholar
  21. 21.
    Kanno K, Tazuma S, Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl4. Biochem Biophys Res Commun, 2003,308(1): 177–183PubMedCrossRefGoogle Scholar
  22. 22.
    Wei YH, Jun L, Qiang CJ. Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats. Dig Dis Sci, 2004,49(10):1589–1594PubMedCrossRefGoogle Scholar
  23. 23.
    Shen FJ, Zhu YK, Jia JD, et al. The effect of angiotensin II type 1 receptor blocker valsartan in preventing hepatic fibrosis induced by dimethylnitrosamine in rats. Zhonghua Gan Zang Bing Za Zhi (Chinese), 2004,12(10):605–608Google Scholar
  24. 24.
    Ueki M, Koda M, Yamamoto S, et al. Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol, 2006,41(10):996–1004PubMedCrossRefGoogle Scholar
  25. 25.
    Dong R, Chen XY, Wu TX, et al. Elemene for the treatment of lung cancer. Cochrane Database Syst Rev, 2007,17(4):CD006054Google Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag GmbH 2009

Authors and Affiliations

  • Rui Zhu (朱锐)
    • 1
  • Ling Yang (杨玲)
    • 2
  • Lin Shen (沈霖)
    • 1
  • Jin Ye (叶进)
    • 2
  • Jianguo Liu (刘建国)
    • 1
  • Shenjun Hu (胡胜军)
    • 1
  1. 1.Department of Traditional Chinese MedicineHuazhong University of Science and TechnologyWuhanChina
  2. 2.Huazhong University of Science and TechnologyWuhanChina

Personalised recommendations